Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Epigallocatechin, most commonly found in green tea as epigallocatechin gallate (EGCG), has been investigated for its potential benefits to prostate health, primarily in the context of prostate cancer risk and benign prostatic hyperplasia (BPH). Several laboratory and animal studies have shown that EGCG can inhibit the proliferation of prostate cancer cells and may induce apoptosis (programmed cell death) in these cells. Additionally, some small-scale human clinical studies and epidemiological data suggest that higher green tea consumption could be associated with a reduced risk of developing prostate cancer. However, these results are not entirely consistent, and large, well-controlled clinical trials are lacking.

For non-cancerous prostate issues such as BPH, the evidence is much more limited. Most human studies focus on cancer prevention rather than general prostate health. Mechanistically, EGCG is thought to exert antioxidant and anti-inflammatory effects, which might contribute to its protective role. Despite some promising preclinical and early clinical evidence, the overall strength of evidence supporting the use of epigallocatechin specifically for prostate health is modest, and more rigorous research is needed before strong recommendations can be made. Thus, the evidence rating is 2 out of 5, reflecting limited but suggestive scientific support.

More about Epigallocatechin
More about Prostate

Other ingredients that support Prostate

Other body systems supported by Epigallocatechin

Products containing Epigallocatechin